Doxorubicin Induced Cardiomyopathy Not Yet Recruiting Phase 2 Trials for Dapagliflozin (DB06292)

IndicationStatusPhase
DBCOND0078390 (Doxorubicin Induced Cardiomyopathy)Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT06427226Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced CardiotoxicityPrevention